Related Experiment Video

Updated: Jan 3, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia

Adam S Kittai1, Jennifer A Woyach

  • 1From the Ohio State University Comprehensive Cancer Center, Columbus, OH.

Cancer Journal (Sudbury, Mass.)
|November 26, 2019
PubMed

Insights

New targeted therapies for chronic lymphocytic leukemia (CLL) show promise, but acquired resistance remains a challenge. Understanding resistance mechanisms is crucial for improving patient outcomes in CLL treatment.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Targeted therapies, including Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib) and B-cell leukemia/lymphoma-2 (BCL-2) inhibitors (e.g., venetoclax), are approved for chronic lymphocytic leukemia (CLL).
  • These agents target specific survival pathways implicated in CLL pathogenesis, improving clinical outcomes in both treatment-naive and relapsed/refractory settings.

Purpose of the Study:

  • To review current data on the development of acquired resistance to targeted therapies in chronic lymphocytic leukemia (CLL).
  • To discuss mechanisms of resistance and areas of ongoing research for overcoming treatment failure in CLL.

Main Methods:

  • Literature review of studies investigating targeted therapy resistance in chronic lymphocytic leukemia.
  • Analysis of data on resistance mechanisms, including direct target mutations and alternative pathway activation.

Main Results:

  • Acquired resistance to targeted agents like ibrutinib and venetoclax is a significant clinical issue in CLL management.
  • Resistance can arise from mutations in the targeted proteins or through the upregulation of parallel survival pathways.
  • Identifying predictive markers for resistance and developing strategies to overcome it are critical research priorities.

Conclusions:

  • Despite improved efficacy, acquired resistance limits the long-term success of targeted therapies in CLL.
  • Further research is essential to elucidate resistance mechanisms and guide the development of novel therapeutic strategies for CLL patients who develop resistance.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
2.5K